Exhibit 99.1 ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid revenue and profit growth Completes full transition and right sized operation in Q4 from clinical lab to cutting edge genomics lab Company to hold a conference call Friday ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-21617 Delaware 23-2577138 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2023 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Yi Chen - H.C. Wainwright Hunter Diamond - Diamond Equity Dennis Waldman - Barrett Productions Operator Good day and welcome the ProPhase Labs Incorporated Third Quarter 2023 Financial Results and Corporate Update. All participants will be in listen-only mode. [Operator Instructions] After today's present ...

Financial Data and Key Metrics Changes - The company reported approximately $38 million in accounts receivable at the end of June, an increase from $37 million at year-end [7][102][111] - Adjusted EBITDA was negative $2.2 million in the second quarter, showing improvement compared to the first quarter [110] Business Line Data and Key Metrics Changes - The company is focusing on expanding its genetic testing business, particularly through Nebula Genomics, which is expected to grow significantly [5][19][54] - The Pharmaloz manufacturing facility is projected to ramp up capacity to $25 million or $35 million, with expectations of filling that capacity [69] Market Data and Key Metrics Changes - The company is experiencing high interest levels for its genetic testing services, similar to the initial interest seen during the COVID testing phase [100][42] - The market for personalized precision medicine is anticipated to grow substantially, with the company positioned to capitalize on this trend [5][19] Company Strategy and Development Direction - The company aims to build a leading laboratory for whole genome sequencing and genetic testing, focusing on increasing capacity and efficiency [42][54] - There is a strategic emphasis on not pursuing dilutive financing options, instead leveraging existing assets and accounts receivable for growth [16][112] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future growth potential of the genetic testing market, indicating that the company is in the early stages of this business [5][19] - The company is not focused on COVID testing anymore, despite a potential uptick in demand, and is instead concentrating on long-term growth in genomics [25][46] Other Important Information - The company is currently validating its lab capabilities and expects to start testing soon, with significant inquiries already being received [100][106] - Management highlighted the potential of the esophageal cancer test, suggesting it could have multibillion-dollar potential [108] Q&A Session Summary Question: Concerns about cash trajectory and liquidity - Management reassured that cash flow is strong and accounts receivable is not an issue, with options available for financing without dilutive measures [15][16][112] Question: Updates on the esophageal cancer test commercialization - Management indicated that they are optimistic about completing studies and obtaining CPT codes, which will facilitate commercialization [56][34] Question: Potential for the Equivir product - Management expressed excitement about Equivir's long-term potential in the immune defense market, with plans for online sales and eventual retail distribution [51][50] Question: Future of the NAVB acquisition offer - Management stated that the offer for NAVB is currently uncertain, but they see potential value in the assets [61][62] Question: Focus on international opportunities - Management emphasized the importance of focusing on domestic growth first, particularly in the Nebula Genomics and Pharmaloz businesses, before expanding internationally [72][68]

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company's H1 2023 financial statements reflect a significant revenue decline and net loss, driven by reduced diagnostic demand, with increased assets and liabilities from acquisitions and debt, and negative operating cash flow [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2023, total assets increased to $91.1 million, liabilities rose to $31.8 million due to new debt, and stockholders' equity decreased to $59.3 million Condensed Consolidated Balance Sheet Summary (in thousands) | Account | June 30, 2023 (Unaudited) | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $3,824 | $9,109 | | Total current assets | $54,966 | $60,833 | | Intangible assets, net | $13,769 | $8,475 | | **TOTAL ASSETS** | **$91,058** | **$87,648** | | **Liabilities & Equity** | | | | Total current liabilities | $13,675 | $16,075 | | Total liabilities | $31,801 | $24,017 | | Total stockholders' equity | $59,257 | $63,631 | | **TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY** | **$91,058** | **$87,648** | [Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20%28Loss%29) Q2 2023 reported a $3.4 million net loss, a sharp reversal from Q2 2022's net income, primarily due to a 50%+ revenue drop to $13.2 million Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2023 | Q2 2022 | Six Months 2023 | Six Months 2022 | | :--- | :--- | :--- | :--- | :--- | | Revenues, net | $13,217 | $29,092 | $32,520 | $76,623 | | Gross profit | $6,448 | $18,720 | $16,968 | $47,397 | | (Loss) income from operations | $(4,658) | $10,587 | $(3,783) | $26,733 | | Net (loss) income | $(3,440) | $7,446 | $(2,890) | $19,940 | | Basic EPS | $(0.20) | $0.48 | $(0.17) | $1.28 | | Diluted EPS | $(0.20) | $0.40 | $(0.17) | $1.07 | [Condensed Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Stockholders' equity decreased to $59.3 million by June 30, 2023, primarily due to a $2.9 million net loss and $5.9 million in treasury stock repurchases - Key changes in stockholders' equity for the six months ended June 30, 2023 include a net loss of **$2.89 million**, stock repurchases of **$0.59 million**, and treasury shares repurchased for tax withholding of **$5.38 million**[16](index=16&type=chunk) - In contrast, for the six months ended June 30, 2022, the company had a net income of **$19.94 million** and paid cash dividends totaling **$9.35 million**[16](index=16&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) H1 2023 saw a significant shift to net cash used in operating activities of $6.5 million, leading to an overall $5.3 million decrease in cash and cash equivalents Cash Flow Summary (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Net cash (used in) provided by operating activities | $(6,481) | $25,108 | | Net cash (used in) provided by investing activities | $(437) | $3,596 | | Net cash provided by (used in) financing activities | $1,633 | $(13,403) | | **(Decrease) increase in cash** | **$(5,285)** | **$15,301** | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail business structure, accounting policies, and key events, including the BE-Smart acquisition, new debt, stock repurchase program, and segment performance - The company operates through two segments: diagnostic services (COVID-19 testing, genomics) and consumer products (contract manufacturing, dietary supplements). It has recently expanded into biopharma and cancer diagnostics[20](index=20&type=chunk)[21](index=21&type=chunk)[24](index=24&type=chunk) - In January 2023, the company acquired the BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test from Stella Diagnostics for total consideration of **$6.8 million**, accounted for as an asset acquisition[44](index=44&type=chunk)[45](index=45&type=chunk)[48](index=48&type=chunk) - In January 2023, the company issued a **$7.6 million** unsecured promissory note due 2026 with a **10%** interest rate, along with warrants to purchase **76,000** shares[51](index=51&type=chunk)[52](index=52&type=chunk) - A new stock repurchase program was approved in March 2023, authorizing the repurchase of up to **$6.0 million** of common stock over six months[61](index=61&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes revenue and profitability decline to decreased COVID-19 testing, noting consumer product growth and increased expenses, while affirming sufficient liquidity despite cash decrease and program risks Q2 2023 vs Q2 2022 Performance (in millions) | Metric | Q2 2023 | Q2 2022 | Change | | :--- | :--- | :--- | :--- | | Net Revenue | $13.2 | $29.1 | $(15.9) | | Gross Profit | $6.4 | $18.7 | $(12.3) | | Net (Loss) Income | $(3.4) | $7.4 | $(10.8) | - The decrease in diagnostic services revenue was driven by a drop in testing volume from **521,000** tests in H1 2022 to **246,000** in H1 2023[143](index=143&type=chunk) - Revenue from the HRSA uninsured program, which constituted **79.1%** of diagnostic revenue in H1 2022, was zero in H1 2023 as the program stopped accepting claims in March 2022[143](index=143&type=chunk)[162](index=162&type=chunk) - General and administration expenses increased by **$3.6 million** in Q2 2023 compared to Q2 2022, due to higher personnel, marketing, and professional fees for strategic initiatives[138](index=138&type=chunk)[139](index=139&type=chunk) - Cash and cash equivalents decreased by **$5.3 million** during the first six months of 2023 to **$3.8 million**. Management believes current liquidity is sufficient to fund operations for at least the next 12 months[157](index=157&type=chunk)[158](index=158&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=36&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company faces no material foreign currency or interest rate risks, but acknowledges potential adverse impacts from broad economic conditions on its business - The company does not have material exposure to foreign currency fluctuations or derivative financial instruments[180](index=180&type=chunk) - A one percentage point change in short-term interest rates is not expected to have a material impact on earnings, fair value, or cash flows[180](index=180&type=chunk) - The company acknowledges that adverse economic conditions, including reduced consumer spending and financial market volatility, could negatively affect its business, including the collection of receivables and asset recoverability[181](index=181&type=chunk) [Item 4. Controls and Procedures](index=37&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including CEO and CFO, deemed disclosure controls and procedures effective as of June 30, 2023, with no material changes to internal controls - Management, including the principal executive officer and principal financial officer, concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2023[184](index=184&type=chunk) - No material changes to internal control over financial reporting occurred during the most recent quarter[185](index=185&type=chunk) [PART II. OTHER INFORMATION](index=38&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=38&type=section&id=Item%201.%20Legal%20Proceedings) The company is not a party to material litigation, but its subsidiary, TK Supplements, Inc., is defending a class action lawsuit alleging false advertising - A purported class action lawsuit was filed on April 27, 2023, against the company's subsidiary, TK Supplements, Inc., alleging false advertising of its Legendz XL male enhancement supplement in violation of California's Consumer Legal Remedies Act[188](index=188&type=chunk) - The company believes the lawsuit is without merit and plans to defend against the litigation vigorously[188](index=188&type=chunk) [Item 1A. Risk Factors](index=38&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors previously disclosed in the company's Annual Report on Form 10-K filed on March 29, 2023, have occurred - As of the filing date of this Form 10-Q, there have been no material changes to the risk factors disclosed in the company's Annual Report on Form 10-K filed on March 29, 2023[190](index=190&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=38&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company issued a warrant for 250,000 shares at $9.00 per share and repurchased 6,012 shares at an average of $7.94 per share - On April 6, 2023, the company issued a warrant to Vencap Consulting LLC to purchase **250,000** shares of common stock at an exercise price of **$9.00** per share, with a five-year term. This was issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act[191](index=191&type=chunk)[192](index=192&type=chunk) Issuer Purchases of Equity Securities (Q2 2023) | Period | Total Shares Purchased | Average Price Paid per Share | Approximate Dollar Value of Shares that May Yet Be Purchased | | :--- | :--- | :--- | :--- | | April 2023 | 6,012 | $7.94 | $5,411,119 | | May 2023 | — | — | $5,411,119 | | June 2023 | — | — | $5,411,119 | | **Total** | **6,012** | **$7.94** | **$5,411,119** | [Item 3. Defaults Upon Senior Securities](index=39&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities during the period - None[194](index=194&type=chunk) [Item 4. Mine Safety Disclosures](index=39&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[194](index=194&type=chunk) [Item 5. Other Information](index=39&type=section&id=Item%205.%20Other%20Information) The company reported no other information for this item - None[194](index=194&type=chunk) [Item 6. Exhibits](index=40&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including bylaws, warrants, equity plans, and CEO/CFO certifications [Signatures](index=41&type=section&id=Signatures)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) | Delaware | 23-2577138 | | --- | --- | | (Sta ...

Financial Data and Key Metrics Changes - The company is not focused on earnings this year, with expectations of losing money, but emphasizes the underlying value of its assets is growing significantly, which is believed to exceed its market cap [3][21][50] - The company reported a profit in the first quarter, but this is not seen as a significant factor in the overall value being built [3][21] Business Line Data and Key Metrics Changes - COVID testing revenues are expected to continue to decline as the public health emergency has ended, and the company is entering its seasonally weakest quarters [2][3] - The Nebula Genomics business is growing at over 100% year-over-year, although it operates from a smaller base [2][3] - The company is diversifying its lab operations beyond COVID testing to include a full clinical lab and whole genome sequencing, with significant growth potential anticipated [11][12][13] Market Data and Key Metrics Changes - The company is targeting a market for esophageal cancer testing that could be worth between $2 billion to $14 billion, with low competition and a significant number of potential endoscopies per year [40][46] - The company expects to commercialize its esophageal cancer test early next year, which is projected to have a substantial market impact [40][46] Company Strategy and Development Direction - The company is focused on building long-term value rather than short-term profits, with a strategy to develop multiple billion-dollar assets [20][27][50] - There is a strong emphasis on global expansion for its products and services, particularly in genomics and cancer testing [30][32][34] - The company is working on synergies between its various subsidiaries to enhance the development of its cancer-related products [38] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges of the current operating environment but remains optimistic about the future potential of its assets [3][20][27] - The company is focused on developing its assets and believes that long-term investors will be rewarded as the underlying value grows [27][50] Other Important Information - The company has established relationships with leading global manufacturers and is well-positioned in the genomics field [12][45] - The company has a manufacturing facility that is currently at capacity, with significant demand for its products [21][52] Q&A Session Summary Question: Could you comment on the current trend of COVID testing and non-COVID testing volume? - Management indicated that COVID testing is expected to slow down significantly as the public health emergency has ended, and the company is entering its seasonally weakest quarters [2] Question: How many sales reps are needed for the esophageal cancer test? - Management stated that a large sales force is not necessary; instead, the focus is on getting key opinion leaders and cancer institutions to support the test [6] Question: What is needed to complete the CLIA lab and how long will it take? - Management confirmed that they are waiting for validations to be completed before ramping up the clinical lab operations, which is expected to start later this year [11] Question: What are the company's ambitions in oncology? - Management highlighted the synergies between various subsidiaries and the potential for the Linebacker compound as both a co-therapy and an individual cancer drug [38]

Financial Performance - As of December 31, 2022, the company had working capital of approximately $40.7 million, sufficient to support its businesses for at least the next twelve months[142]. - Revenues for the year ended December 31, 2022, increased to $122.647 million, up 55% from $79.042 million in 2021[383]. - Gross profit for 2022 was $70.654 million, representing a gross margin of approximately 57.6%, compared to $41.988 million in 2021[383]. - Net income for 2022 was $18.463 million, a significant increase from $6.273 million in 2021, reflecting a growth of 194%[389]. - Basic earnings per share rose to $1.17 in 2022, compared to $0.41 in 2021, indicating a substantial improvement in profitability[383]. - Cash flows from operating activities for 2022 were $28.551 million, a turnaround from a cash outflow of $13.619 million in 2021[389]. - The company reported a total comprehensive income of $19.395 million for 2022, compared to $6.109 million in 2021, reflecting overall financial growth[383]. - Total operating expenses for 2022 were $47.059 million, up from $32.187 million in 2021, primarily driven by increased diagnostic and administrative expenses[383]. - Stockholders' equity increased to $63.631 million in 2022, up from $58.628 million in 2021, reflecting a stronger equity position[381]. - Total liabilities decreased to $24.017 million in 2022 from $30.667 million in 2021, indicating improved financial health[381]. Business Operations - The company launched its diagnostic service business in October 2020, and its future profitability will depend on the demand for COVID-19 testing and other diagnostic services[172]. - The company acquired Nebula, a personal genomics company, in August 2021, and is integrating its whole genome sequencing services with existing clinical diagnostic services[140]. - The company formed ProPhase Biopharma, Inc. in March 2022 for the licensing, development, and commercialization of novel drugs and dietary supplements[141]. - The company operates two segments: diagnostic services and consumer products, with significant revenue growth attributed to the diagnostic services business line[403]. - The diagnostic services business has seen increased revenues due to demand for COVID-19 testing, primarily from government bodies and large corporations[405]. - The personal genomics business is influenced by demand for genetic sequencing products and regulatory compliance[407]. - The contracting manufacturing business is affected by seasonal demand, particularly during the cold season from September to March[408]. - The company actively pursues acquisition opportunities for technologies and products within and outside the consumer products industry[398]. Market Competition - The company faces significant competition in the lab diagnostic services market from major players like Quest Diagnostics and Laboratory Corporation of America, which have substantial resources[143]. - The personal genomics market has seen increased competition, with many companies entering the space, some with greater financial and technical resources[144]. - Three customers accounted for 53.3% of the company's revenues for the year ended December 31, 2022, with individual contributions of 23.5%, 17.9%, and 11.9%[183]. Regulatory and Compliance Risks - The company must comply with extensive federal, state, and local regulations, including CLIA and HIPAA, to avoid severe consequences that could materially affect its financial condition[184]. - The FDA's regulation of diagnostic products could lead to increased costs and potential fines, impacting the company's business operations[187]. - The company is required to comply with complex laws protecting the privacy and security of health information and personal data, with significant compliance costs[274]. - Noncompliance with privacy laws could result in criminal penalties, civil sanctions, and significant monetary penalties, adversely affecting financial performance[275]. - The California Consumer Privacy Act (CCPA) provides for fines of up to $7,500 per violation, requiring modifications to data processing practices and incurring substantial compliance costs[276]. Operational Challenges - Disruptions in the supply chain, including access to testing supplies and raw materials, could materially impact the company's operations and financial condition[149]. - The complexity of billing and collections for diagnostic tests poses risks, including long collection cycles and lower collection rates, which could adversely affect revenue[176]. - The company faces intense competition for skilled employees, which is critical for its product generation efforts, and failure to retain key personnel could adversely affect operations[169]. - The company must validate any new laboratories according to governmental standards before utilizing their services, which could impact workflow[206]. - Any significant disruption in the company's IT systems could harm its reputation and result in customer loss[207]. Future Outlook - The end of the COVID-19 national emergency on May 11, 2023, may significantly impact the demand for COVID-19 testing services and the company's ability to generate revenue from this segment[175]. - The company may require additional capital to support its growing diagnostic services and personal genomics business, but funding may not be available on acceptable terms[159]. - The personal genomics business's success depends on establishing a market presence and achieving economies of scale, which are critical for financial viability[200]. - The company is early in the development of its product candidates, with revenue generation not expected for several years, highlighting the uncertainty in commercialization[220]. - The success of product candidates depends on various factors, including regulatory approvals, market acceptance, and competition, which are uncertain[222]. Intellectual Property and Legal Risks - The patent position of the company is uncertain, and the ability to protect intellectual property may be compromised, affecting competitive advantage[257]. - The company may face substantial liability from third-party claims of intellectual property infringement, which could delay development efforts[261]. - Protecting and enforcing intellectual property rights could divert financial resources from other business objectives[265]. Acquisitions and Investments - In January 2023, the company acquired exclusive rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test, aimed at early detection of esophageal cancer[397]. - The company has made substantial investments in equipment, supplies, and personnel to support its diagnostic services[405].

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2022 Earnings Conference Call March 28, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and Chief Executive Officer Conference Call Participants Yi Chen - H.C. Wainwright Hunter Diamond - Diamond Equity Research Patrick Patterson - Private Investor Fred McDonald - Private Investor Operator Hello and welcome to the ProPhase Labs Financial Results for the Year Ended December 31, 2022 Conference Call. [Operator Instructions] Please note this event is being recor ...

Financial Data and Key Metrics Changes - The trailing 12-month revenues exceeded $140 million, with adjusted EBITDA over $50 million, indicating strong financial performance despite market conditions [43][46]. - The company reported significant year-over-year revenue growth and earnings, particularly in the diagnostic testing segment, despite seasonal fluctuations [26][46]. Business Line Data and Key Metrics Changes - ProPhase Diagnostics is generating the bulk of revenues and earnings, primarily from COVID testing, which has shown resilience even as market expectations shifted [16][46]. - The dietary supplement businesses are also growing and generating positive earnings, with a potential combined sale value of approximately $25 million [15][46]. Market Data and Key Metrics Changes - The company is positioned to leverage its strong capital base to navigate the bear market, with opportunities to acquire undervalued assets in the biotech and diagnostics sectors [29][51]. - The market for whole genome sequencing is expected to expand significantly, with the company aiming to become a low-cost provider in the U.S. [33][38]. Company Strategy and Development Direction - The company is focused on building out its subsidiaries, particularly in diagnostics and genomics, with plans to introduce new products like Equivir and Linebacker [30][32]. - Strategic partnerships, such as the collaboration with G42 Healthcare, are aimed at enhancing the company's capabilities in whole genome sequencing and expanding its market presence [64][66]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential for significant growth in the diagnostics and genomics sectors, despite current market challenges [51][66]. - The company is committed to maintaining profitability while expanding its operations and exploring new strategic initiatives [51][94]. Other Important Information - The company has a strong capital base, which allows it to manage cash flow effectively and maintain customer loyalty despite industry challenges [81][90]. - The finance department has been strengthened with new hires, enhancing the company's financial management capabilities [78]. Q&A Session Summary Question: Are there other drugs that Linebacker can be used with? - Management confirmed that they are exploring additional applications for Linebacker beyond the initial cancer drugs, with ongoing preclinical studies showing promise [55][56]. Question: Can you provide details on the MOU with G42 and the visit to the UAE? - Management highlighted the strategic importance of the partnership with G42, emphasizing the potential for growth in the U.S. market and the opportunities presented by the thriving capital markets in Abu Dhabi and Dubai [64][66]. Question: What is the current trend in diagnostic services and revenue generation from non-COVID tests? - Management indicated that while PCR testing remains the bulk of the business, there are plans to diversify into non-COVID tests, with expectations for revenue generation in the near future [71][73]. Question: What is the status of accounts receivables and payment timelines? - Management acknowledged the complexities of collecting payments from insurance companies and the impact of HRSA funding issues, but expressed confidence in the company's ability to manage cash flow effectively [81][90]. Question: Are there any upcoming acquisitions being considered? - Management stated that they are actively reviewing strategic initiatives and potential acquisitions, particularly in the biotech space, but emphasized a cautious approach to avoid dilutive financing [92][94].